Efficacy of the Ranger Drug-Coated Balloon in Treating BTK Lesions in Patients With CLTI
A legfontosabb adatok
- Ki végzi
- First Affiliated Hospital, Sun Yat-Sen University
- Hol
- Guangzhou (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 700 fő, tervezett
- Kezdés
- 2025. jún. 30.
- Várható befejezés
- 2029. jan. 1.
- A vizsgálat típusa
- Megfigyeléses
- A vizsgált kezelések
- drug-coated balloon
- A regiszteradat frissítve
- 2025. június 11.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults in China with chronic limb-threatening ischemia, meaning severely reduced blood flow to the leg. They have blockages below the knee and are treated with the Ranger drug-coated balloon.
- Életkor
- 18 years and older
- Nem
- All sexes can join
- A betegség stádiuma
- Chronic limb-threatening ischemia, Rutherford category 4-6, with gangrene on the leg or foot. Below-the-knee narrowings must be ≥ 5 cm (2 in) long with ≥ 70% narrowing, or blockages ≥ 1 cm (0,4 in) long. At least one open vessel below the ankle is needed, and blood must flow freely above the knee.
- Korábbi kezelés
- People who already had an amputation above or below the knee of the leg to be treated cannot join.
A részvétel fő kizáró okai
- Ulcers caused only by vein disease, wounds from injury only, sudden limb ischemia (2 weeks or less), clots carried from elsewhere, or non-atherosclerotic vessel disease such as vasculitis or Buerger's disease
- Life expectancy under 1 year, Alzheimer's disease, or NYHA Class III or IV heart failure
- Bleeding disorders, protein C, protein S or ATIII problems, or being unable to take blood-thinning drugs
- Heart attack, angina or stroke in the past 3 months
- Pregnancy or breastfeeding
A regiszter feltételei, szó szerint
Mind a 21 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥ 18 years, gender is not limited
- The patient agreed to participate in the CEIBA study and signed the written informed consent
- Diagnosis of chronic limb-threatening ischemia (Rutherford category 4-6)
- Gangrene involving any part of the lower extremities or feet, with exclusion of patients who have:; 4.1 Pure venous ulcers 4.2 Pure traumatic wounds 4.3 Acute limb ischemia (symptoms present for 2 weeks or less) 4.4 Embolic disease 4.5 Non-atherosclerotic chronic lower extremity vascular diseases (e.g., vasculitis, Buerger's disease, radiation arteritis)
- Outflow Tract Requirement: At least one direct or indirect, unobstructed outflow vessel in the submalleolar segment of the target limb planned for revascularization
- Lesion Type:; 6.1 Unobstructed blood flow in the suprapopliteal access pathway (including inflow vessels that have been recanalized via staged or concurrent endovascular intervention or hybrid surgery); 6.2 Sub-knee stenotic lesions ≥ 5 cm in length with ≥ 70% diameter reduction. 6.3 Sub-knee occlusive lesions ≥ 1 cm in length. 6.4 Two separate lesions with a minimum 3 cm interval between them may be considered as a single lesion for study inclusion purposes
Ki nem vehet részt
- Concurrent participation in another interventional clinical trial requiring informed consent
- Contraindications to antiplatelet or anticoagulant therapy
- Prior suprapatellar or infrapatellar amputation of the target limb
- Presence of life-threatening diseases or comorbidities with an expected life expectancy of less than 1 year
- Diagnosis of Alzheimer's disease
- Hematologic disorders or known bleeding tendency
- Known allergy to contrast agents that cannot be managed with standard premedication (e.g., steroids)
- New York Heart Association (NYHA) Class III or IV heart failure
- Presence of aneurysm, perforation, dissection, or other target vessel injury requiring intervention
- Presence of other comorbid conditions (unrelated to the index disease) that affect walking function
- History of cardiovascular events within the past 3 months, including nonfatal myocardial infarction, unstable angina, stable angina, nonfatal ischemic stroke, or hemorrhagic stroke
- Any other condition that, in the opinion of the investigator, would interfere with study treatment or functional assessments
- Deficiency or dysfunction of protein C, protein S, or antithrombin III (ATIII)
- Pregnancy or lactation
- Clinically significant liver or renal dysfunction, as determined by the investigator
Helyszínek itt: Kína
- the First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou, KínaContact: Guangqi ChangToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a prospective, multicenter, observational study designed to evaluate the clinical outcomes of the Ranger™ SL paclitaxel-coated balloon, a type of drug-coated balloon (DCB), in the treatment of below-the-knee (BTK) lesions in patients with chronic limb-threatening ischemia (CLTI) in China. All enrolled patients will be followed for six months. Patients diagnosed with CLTI who undergo treatment with the Ranger DCB will be included in the study. The primary outcome is the incidence of major adverse events (MAEs).
A vizsgálat csoportja
- DCB
Ranger drug-coated balloon group
Kezelés: drug-coated balloon
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Efficacy of the Ranger Drug-Coated Balloon in Treating Below-the-Knee Lesions in Patients With Chronic Limb-Threatening Ischemia
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2025. június 11.